Patient characteristics and standardised differences before and after propensity score-matching
| Acute myocardial infarction | |||||||
| Variables | All patients (n=13 680) | Propensity score-matched cohort (n=8696) | |||||
| With hyperlipidemia n=8929 | With no hyperlipidemia n=4751 | Absolute standardised difference | With hyperlipidemia n=4348 | With no hyperlipidemia n=4348 | Absolute standardised difference | ||
| Demographics | Age, years, mean±SD | 67.0±13.6 | 71.3±13.5 | 0.315 | 68.9±13.3 | 70.6±13.6 | 0.122 |
| Male n (%) | 6035 (68) | 2938 (62) | 0.121 | 2761 (64) | 2761 (64) | 0 | |
| White n (%) | 8108 (91) | 3963 (83) | 0.222 | 3744 (86) | 3744 (86) | 0 | |
| Anthropometric measurements | BMI kg/m2 | 30.1±6.2 | 28.8±6.3 | – | 29.8±6.3 | 28.9±6.3 | – |
| BMI, missing n = (%) | 1556 (17) | 1520 (32) | – | 1274 (29) | 1330 (31) | – | |
| Clinical characteristics | LOS, days, median (quartiles 25%–75%) | 3 (2–5) | 4 (3–8) | 0.275 | 4 (3–6) | 4 (3–7) | 0.086 |
| Year of hospital admission | 1996–2005 n (%) 2006–2016 n (%) | 3886 (44) 5043 (57) | 3732 (79) 1019 (21) | 0.770 | 3341 (77) 1007 (23) | 3341 (77) 1007 (23) | 0 |
| Comorbid conditions | CAD, n (%) | – | – | – | – | ||
| Cancer, n (%) | 744 (8) | 342 (7) | 0.042 | 279 (6) | 313 (7) | 0.029 | |
| CKD, n (%) | 885 (12) | 380 (8) | 0.067 | 348 (18) | 353 (8) | 0.004 | |
| COPD, n (%) | 820 (9) | 640 (14) | 0.136 | 482 (11) | 543 (13) | 0.044 | |
| Diabetes, n (%) | 2567 (29) | 1249 (26) | 0.055 | 1091 (295) | 1149 (26) | 0.030 | |
| Heart failure, n (%) | 1762 (20) | 1376 (29) | 0.216 | 1033 (24) | 1173 (27) | 0.075 | |
| Hypertension, n (%) | 6049 (68) | 2584 (54) | 0.277 | 2530 (58) | 2453 (56) | 0.037 | |
| Stroke, n (%) | 359 (4) | 168 (4) | 0.025 | 151 (4) | 148 (3) | 0.004 | |
| Lipid levels | LDL-C mg/dl | 110.9±39.2 | 78.7±25.0 | – | 118.4±37.6 | 78.8±25.1 | – |
| LDL-C, missing n (%) | 483 (5) | 1356 (29) | – | 251 (6) | 1177 (27) | – | |
| Drug treatment | Statin | 4665 (52) | 1431 (30) | 0.461 | 1566 (36) | 1412 (33) | 0.074 |
| Heart failure | |||||||
| Variables | All patients (n=9717) | Propensity score-matched cohort (n=5758) | |||||
| With hyperlipidemia n=3941 | With no hyperlipidemia n=5776 | Absolute standardised difference | With hyperlipidemia n=2879 | With no hyperlipidemia n=2879 | Absolute standardised difference | ||
| Demographics | Age, years, mean±SD | 73.2±12.4 | 73.0±14.5 | 0.020 | 72.6±12.6 | 73.1±14.1 | 0.040 |
| Male n (%) | 2342 (59) | 3266 (57) | 0.058 | 1682 (54) | 1682 (54) | 0 | |
| White n (%) | 3574 (91) | 4896 (85) | 0.181 | 2588 (90) | 2588 (90) | 0 | |
| Anthropometric measurements | BMI kg/m2 | 31.1±7.6 | 29.7±7.5 | – | 31.0±7.6 | 30.0±7.5 | – |
| BMI, missing n (%) | 193 (5) | 780 (13) | – | 185 (6) | 262 (9) | – | |
| Clinical characteristics | LOS, days, median (quartiles 25%–75%) | 4 (2–6) | 4 (2–7) | 0.183 | 4 (2–6) | 4 (2–7) | 0.018 |
| Year of hospital admission | 1996–2005 n (%) 2006–2016 n (%) | 1221 (31) 2720 (69) | 3510 (61) 2266 (39) | 0.626 | 1197 (42) 1682 (58) | 1197 (42) 1682 (58) | 0 |
| Comorbid conditions | CAD, n (%) | 2482 (63) | 2309 (40) | 0.472 | 1580 (55) | 1537 (53) | 0.031 |
| Cancer, n (%) | 595 (15) | 736 (13) | 0.068 | 419 (15) | 420 (15) | 0.001 | |
| CKD, n (%) | 1286 (33) | 1299 (23) | 0.228 | 802 (28) | 819 (28) | 0.013 | |
| COPD, n (%) | 813 (21) | 1152 (20) | 0.017 | 567 (20) | 584 (20) | 0.015 | |
| Diabetes, n (%) | 1617 (41) | 1660 (29) | 0.260 | 1117 (39) | 1015 (35) | 0.075 | |
| Heart failure, n (%) | – | – | – | – | – | – | |
| Hypertension, n (%) | 2911 (74) | 2930 (51) | 0.492 | 1931 (67) | 1869 (65) | 0.046 | |
| Stroke, n (%) | 160 (4) | 106 (2) | 0.132 | 94 (3) | 75 (3) | 0.039 | |
| Lipid levels | LDL-C mg/dl | 92.8±39.9 | 75.5±28.5 | – | 98.5±41.0 | 74.0±28.5 | – |
| LDL-C, missing n (%) | 517 (13) | 2130 (37) | – | 268 (13) | 928 (32) | – | |
| Drug treatment | Statin | 1731 (44) | 963 (17) | 0.621 | 906 (32) | 800 (28) | 0.084 |
BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; LDL-C, low-density lipoprotein cholesterol; LOS, length of stay.